Cendifensine (INNTooltip International Nonproprietary Name) is a monoamine reuptake inhibitor (MRI)[1] related to the amphetamines and cathinones which has not been marketed at this time.

[2][3][4] It was first described by 2013[4] and its INNTooltip International Nonproprietary Name was proposed in 2024.

[2] The drug has been patented by Noema Pharma, which is developing a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) known as NOE-115 for the treatment of vasomotor symptoms as well as for binge-eating disorder and depressive disorders.

[5][6][7] This psychoactive drug-related article is a stub.

You can help Wikipedia by expanding it.